Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion

Elizabeth D. Feldman, Peter C. Wu, Tatiana Beresneva, Cynthia Helsabeck, Montessa Rodriguez, David L. Bartlett, Steven K. Libutti, James F. Pingpank, H. Richard Alexander

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Primary hepatocellular carcinoma is one of the most common malignancies worldwide. Isolated hepatic perfusion (IHP) is a regional treatment technique that isolates the organ to allow delivery of high-dose chemotherapy, biological agents, and hyperthermia directly to unresectable cancers confined to the liver. This study presents our experience using IHP with melphalan with or without tumor necrosis factor (TNF) to treat patients with hepatocellular carcinoma or adenocarcinoma of hepatobiliary origin. Nine patients with unresectable primary hepatic malignancies underwent a 60-minute IHP with 1.5 mg/kg melphalan with or without 1.0 mg TNF. Four patients failed one or more previous treatment regimens, and the mean hepatic replacement by tumor was 41% (range 10% to 75%). Patients were monitored for response, toxicity, time to recurrence, and survival. Six (67%) of nine patients experienced greater than 50% regression of tumor by objective radiographic imaging and an additional patient had a 45% reduction in tumor burden. Mean time to progression was 7.7 months for those who responded to treatment. Patients who had a response to therapy had an average overall survival of 16.3 months. IHP can be performed safely and has significant antitumor activity in patients with unresectable primary hepatic malignancies. Hepatic progession continues to be the dominant factor influencing survival in this group of patients.

Original languageEnglish (US)
Pages (from-to)200-207
Number of pages8
JournalJournal of Gastrointestinal Surgery
Volume8
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Perfusion
Liver
Neoplasms
Melphalan
Therapeutics
Survival
Hepatocellular Carcinoma
Tumor Necrosis Factor-alpha
Biological Factors
Tumor Burden
Adenocarcinoma
Fever
Recurrence
Drug Therapy

Keywords

  • Hyperthermia
  • Liver neoplasms
  • Regional perfusion

ASJC Scopus subject areas

  • Surgery

Cite this

Feldman, E. D., Wu, P. C., Beresneva, T., Helsabeck, C., Rodriguez, M., Bartlett, D. L., ... Alexander, H. R. (2004). Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. Journal of Gastrointestinal Surgery, 8(2), 200-207. https://doi.org/10.1016/j.gassur.2003.11.005

Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. / Feldman, Elizabeth D.; Wu, Peter C.; Beresneva, Tatiana; Helsabeck, Cynthia; Rodriguez, Montessa; Bartlett, David L.; Libutti, Steven K.; Pingpank, James F.; Alexander, H. Richard.

In: Journal of Gastrointestinal Surgery, Vol. 8, No. 2, 02.2004, p. 200-207.

Research output: Contribution to journalArticle

Feldman, ED, Wu, PC, Beresneva, T, Helsabeck, C, Rodriguez, M, Bartlett, DL, Libutti, SK, Pingpank, JF & Alexander, HR 2004, 'Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion', Journal of Gastrointestinal Surgery, vol. 8, no. 2, pp. 200-207. https://doi.org/10.1016/j.gassur.2003.11.005
Feldman, Elizabeth D. ; Wu, Peter C. ; Beresneva, Tatiana ; Helsabeck, Cynthia ; Rodriguez, Montessa ; Bartlett, David L. ; Libutti, Steven K. ; Pingpank, James F. ; Alexander, H. Richard. / Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. In: Journal of Gastrointestinal Surgery. 2004 ; Vol. 8, No. 2. pp. 200-207.
@article{12357cb3e4b44ab7943acde2d5a15ac5,
title = "Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion",
abstract = "Primary hepatocellular carcinoma is one of the most common malignancies worldwide. Isolated hepatic perfusion (IHP) is a regional treatment technique that isolates the organ to allow delivery of high-dose chemotherapy, biological agents, and hyperthermia directly to unresectable cancers confined to the liver. This study presents our experience using IHP with melphalan with or without tumor necrosis factor (TNF) to treat patients with hepatocellular carcinoma or adenocarcinoma of hepatobiliary origin. Nine patients with unresectable primary hepatic malignancies underwent a 60-minute IHP with 1.5 mg/kg melphalan with or without 1.0 mg TNF. Four patients failed one or more previous treatment regimens, and the mean hepatic replacement by tumor was 41{\%} (range 10{\%} to 75{\%}). Patients were monitored for response, toxicity, time to recurrence, and survival. Six (67{\%}) of nine patients experienced greater than 50{\%} regression of tumor by objective radiographic imaging and an additional patient had a 45{\%} reduction in tumor burden. Mean time to progression was 7.7 months for those who responded to treatment. Patients who had a response to therapy had an average overall survival of 16.3 months. IHP can be performed safely and has significant antitumor activity in patients with unresectable primary hepatic malignancies. Hepatic progession continues to be the dominant factor influencing survival in this group of patients.",
keywords = "Hyperthermia, Liver neoplasms, Regional perfusion",
author = "Feldman, {Elizabeth D.} and Wu, {Peter C.} and Tatiana Beresneva and Cynthia Helsabeck and Montessa Rodriguez and Bartlett, {David L.} and Libutti, {Steven K.} and Pingpank, {James F.} and Alexander, {H. Richard}",
year = "2004",
month = "2",
doi = "10.1016/j.gassur.2003.11.005",
language = "English (US)",
volume = "8",
pages = "200--207",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion

AU - Feldman, Elizabeth D.

AU - Wu, Peter C.

AU - Beresneva, Tatiana

AU - Helsabeck, Cynthia

AU - Rodriguez, Montessa

AU - Bartlett, David L.

AU - Libutti, Steven K.

AU - Pingpank, James F.

AU - Alexander, H. Richard

PY - 2004/2

Y1 - 2004/2

N2 - Primary hepatocellular carcinoma is one of the most common malignancies worldwide. Isolated hepatic perfusion (IHP) is a regional treatment technique that isolates the organ to allow delivery of high-dose chemotherapy, biological agents, and hyperthermia directly to unresectable cancers confined to the liver. This study presents our experience using IHP with melphalan with or without tumor necrosis factor (TNF) to treat patients with hepatocellular carcinoma or adenocarcinoma of hepatobiliary origin. Nine patients with unresectable primary hepatic malignancies underwent a 60-minute IHP with 1.5 mg/kg melphalan with or without 1.0 mg TNF. Four patients failed one or more previous treatment regimens, and the mean hepatic replacement by tumor was 41% (range 10% to 75%). Patients were monitored for response, toxicity, time to recurrence, and survival. Six (67%) of nine patients experienced greater than 50% regression of tumor by objective radiographic imaging and an additional patient had a 45% reduction in tumor burden. Mean time to progression was 7.7 months for those who responded to treatment. Patients who had a response to therapy had an average overall survival of 16.3 months. IHP can be performed safely and has significant antitumor activity in patients with unresectable primary hepatic malignancies. Hepatic progession continues to be the dominant factor influencing survival in this group of patients.

AB - Primary hepatocellular carcinoma is one of the most common malignancies worldwide. Isolated hepatic perfusion (IHP) is a regional treatment technique that isolates the organ to allow delivery of high-dose chemotherapy, biological agents, and hyperthermia directly to unresectable cancers confined to the liver. This study presents our experience using IHP with melphalan with or without tumor necrosis factor (TNF) to treat patients with hepatocellular carcinoma or adenocarcinoma of hepatobiliary origin. Nine patients with unresectable primary hepatic malignancies underwent a 60-minute IHP with 1.5 mg/kg melphalan with or without 1.0 mg TNF. Four patients failed one or more previous treatment regimens, and the mean hepatic replacement by tumor was 41% (range 10% to 75%). Patients were monitored for response, toxicity, time to recurrence, and survival. Six (67%) of nine patients experienced greater than 50% regression of tumor by objective radiographic imaging and an additional patient had a 45% reduction in tumor burden. Mean time to progression was 7.7 months for those who responded to treatment. Patients who had a response to therapy had an average overall survival of 16.3 months. IHP can be performed safely and has significant antitumor activity in patients with unresectable primary hepatic malignancies. Hepatic progession continues to be the dominant factor influencing survival in this group of patients.

KW - Hyperthermia

KW - Liver neoplasms

KW - Regional perfusion

UR - http://www.scopus.com/inward/record.url?scp=1242276303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242276303&partnerID=8YFLogxK

U2 - 10.1016/j.gassur.2003.11.005

DO - 10.1016/j.gassur.2003.11.005

M3 - Article

C2 - 15036196

AN - SCOPUS:1242276303

VL - 8

SP - 200

EP - 207

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 2

ER -